Matching articles for "dostarlimab"
In Brief: A New Endometrial Cancer Indication for Dostarlimab (Jemperli) (online only)
The Medical Letter on Drugs and Therapeutics • August 21, 2023; (Issue 1683)
The immune checkpoint inhibitor dostarlimab-gxly
(Jemperli – GSK) has been approved by the FDA for
use in combination with carboplatin and paclitaxel
for treatment of adults with mismatch repair...
The immune checkpoint inhibitor dostarlimab-gxly
(Jemperli – GSK) has been approved by the FDA for
use in combination with carboplatin and paclitaxel
for treatment of adults with mismatch repair deficient
(dMMR) or microsatellite instability-high (MSI-H)
primary advanced or recurrent endometrial cancer.
Dostarlimab was recently granted regular approval
for treatment of adults with dMMR recurrent or
advanced endometrial cancer that progressed on
or following a prior platinum-containing regimen in
any setting and who are not candidates for curative
surgery or radiation.
Dostarlimab (Jemperli) for Endometrial Cancer (online only)
The Medical Letter on Drugs and Therapeutics • April 3, 2023; (Issue 1673)
The FDA has granted regular approval to dostarlimabgxly
(Jemperli – GSK), an immune checkpoint
inhibitor, for treatment of adults with mismatch repair
deficient (dMMR) recurrent or advanced...
The FDA has granted regular approval to dostarlimabgxly
(Jemperli – GSK), an immune checkpoint
inhibitor, for treatment of adults with mismatch repair
deficient (dMMR) recurrent or advanced endometrial
cancer that has progressed on or following a prior
platinum-containing regimen in any setting and who
are not candidates for curative surgery or radiation.
Dostarlimab received accelerated approval in 2021
for treatment of adults with dMMR recurrent or
advanced endometrial cancer or nonendometrial
solid tumors that progressed on or following prior
treatment and who have no satisfactory alternative
treatment options. About 25-30% of patients with
endometrial cancer have dMMR tumors.